Aarti Industries Ltd

Meeting Details

• Date: September 01, 2026; time not disclosed.
• Event: Ashwamedh-Elara India Dialogue 2026.
• Meeting type: Mix of one-on-one and group meetings.
• Place: Grand Hyatt, Mumbai.

Participants

• Participants: Company officials (roles not specified).

Purpose

• Purpose: Analyst/Investor Meet attendance by company officials.

Financial Performance

• Revenue Rs 2,627 crore, up 41% YoY.
• EBITDA Rs 385 crore, up 79% YoY.
• PAT Rs 155 crore, up 260% YoY.
• Working capital expansion raised debt and finance costs.
• FY27 CAPEX guidance Rs 700-800 crore; Rs 180 crore deployed in Q1 FY27.

Operating Update

• Energy business volumes steady; West Asia revenue share fell to 2%.
• Energy capacity expanded to 360 KTPA from 290 KTPA.
• Non-energy demand mixed; polymers soft; dyes headwinds; pharma stable; agro volumes lower.
• NCB value chain exports benefited from China export tax rebates suspension.
• Zone IV delays; five chemistries; commissioning FY27–FY29; Augene and RESL to commission.
• MPP and calcium chloride unit to commission this year.
• Zone IV ramp-up slower than plan; 2–4 quarters to PAT impact.
• Exports 59% of revenue; volumes to rise in Q2.

Capex and Projects

• Augene JV commissioning planned in Q2 FY27; 50-50 PAT consolidation.
• SABIC backward integration project; commissioning Sep-Oct 2027.
• Zone IV chlorotoluene delays due to labor shortages; 97% equipment erected; 85% piping.
• Energy capacity expansion to 360 KTPA completed; ramp-up over next 12 months.

Guidance and Outlook

• FY27 CAPEX on track; Rs 700-800 crore; Rs 180 crore deployed in Q1.
• Capex intensity to reduce from next year; focus on high-growth niche projects.
• Zone IV ramp-up expected in 2–4 quarters; Augene contribution visible in PAT.
• Exports share 59% of revenue; volumes to rise in Q2.

Q&A Highlights

• Rohit Nagraj asks Zone IV ramp impact on FY28; management confirms ramp and on-track JVs.
• Inventory and FX gains estimated at INR 50-60 crore; volatility explained.
• Arun Prasath asks Augene steady-state; first sale happened; ramp 1–2 years.
• Aditya Khetan asks EBITDA trajectory; volatility cited; underlying performance discussed.
• Archit Joshi asks SABIC backward integration timeline; completion around Sep-Oct 2027.

Meeting Details

• Aug 11, 2026; Nuvama India Conference: Shoring up Self-Reliance; mix of one-on-one and group meetings, Singapore; company officials.
• Aug 12–14, 2026; Avendus Spark INDX- Asia Edition 2026; mix of meetings, Hong Kong and Singapore; company officials.

Committee changes

• Committee renamed to Risk Management and ESG Committee.
• Nikhil J. Bhatia inducted as Independent Director and member effective 30 July 2026.
• No change to Committee chair; other members unchanged.
• Effective from 30 July 2026.

Meeting Details

• Intimation for investor/analyst quarterly earnings conference call issued July 21, 2026.
• Audio recording of the call for quarter ended June 30, 2026 uploaded on the company website.
• Event: Investor/Analyst Quarterly Earnings Conference Call.

Purpose

• Purpose: discuss the company's financial results for the quarter ended June 30, 2026.

Business Overview

• Core business: specialty chemicals with integrated operations.
• Strategic focus on capacity expansion, downstream integration, and sustainability initiatives.

Operational Highlights

• Fuel additives capacity expanded to 360 KTPA in July 2026.
• JV with Augene and Superform near commissioning; commercialisation in Q2 FY27.
• Chemical recycling of plastics: equipment delivered; commissioning expected H2 FY27.

Financial Performance

• Revenue rose on input price pass-through; ME region impact mitigated by alternate markets.
• Q1 FY27 EBITDA growth supported by low-cost inventory monetisation and FX gains.
• Working capital uptick due to higher input costs and export mix; higher debt.

Capital Structure & Liquidity

• Working capital increased due to input prices and exports, raising debt and financing costs.

Strategic Priorities & Outlook

• 3-year plan focuses on cost optimisation, volume/margin ramp-up, and CAPEX-led growth.
• Target EBITDA ₹1,800-2,200 Cr; Debt/EBITDA < 2.5x.
• Capex: Augene, Re Aarti JV commissioning; Zone 4; MPP commercialization.

Risks & Mitigation

• West Asia crisis caused RM price volatility; mitigated via product/geography mix.
• Labour constraints delaying Zone 4 and plastics recycling timelines; mitigation: alternative suppliers.

Governance & Leadership

• JV partnerships and management updates: Augene and Re Aarti JV on track.
• Sustainability initiatives: Ecovadis Platinum rating 87/100.

Promoter-to-public reclassification

• Board approves reclassification of promoter to public for Ratanben Premji Gogri's 13,77,330 shares (0.38%).
• Approval is subject to stock exchange approvals and required compliance steps.

Leadership transition

• Board approves Suyog Kotecha as MD & CEO effective Oct 1, 2026, subject to shareholders' approval.
• Promoter Directors to transition to non-executive leadership roles from Oct 1, 2026.
• Transition aligns with long-term succession planning and governance strengthening.
• Kotecha previously CEO since June 2024; Board conveys confidence in continued growth.
• Leadership transition does not alter long-term strategic direction.
• Promoter leadership to provide strategic oversight through non-exec board roles.